Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI atai Life Sciences	$2.70 +1.9%	$2.23	$1.03 ▼ $2.99	$530.90M	1.44	2.10 million shs	2.24 million shs
DNLI Denali Therapeutics	$14.87 +4.9%	$14.24	$10.57 ▼ $33.33	$2.06B	1.33	1.14 million shs	2.45 million shs
INDV Indivior	$15.60 +1.4%	$13.39	$7.33 ▼ $15.91	N/A	0.65	1.22 million shs	1.75 million shs
RXRX Recursion Pharmaceuticals	$5.39 +3.3%	$4.87	$3.79 ▼ $12.36	$2.12B	0.91	16.73 million shs	24.23 million shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI atai Life Sciences	+1.89%	+1.50%	+20.54%	+83.67%	+64.63%
DNLI Denali Therapeutics	+4.94%	-0.87%	+1.71%	+16.72%	-37.89%
INDV Indivior	+1.43%	+3.04%	+10.01%	+73.14%	+51.31%
RXRX Recursion Pharmaceuticals	+3.26%	-3.58%	+7.80%	-2.00%	-37.33%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI atai Life Sciences	3.1732 of 5 stars	3.8	4.0	0.0	2.4	1.7	0.6
DNLI Denali Therapeutics	4.6842 of 5 stars	4.5	1.0	4.7	3.9	3.3	0.0
INDV Indivior	1.2235 of 5 stars	1.6	1.0	0.0	2.2	1.7	1.9
RXRX Recursion Pharmaceuticals	1.857 of 5 stars	3.2	2.0	0.0	1.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI atai Life Sciences	3.50	Strong Buy	$9.00	233.33% Upside
DNLI Denali Therapeutics	3.06	Buy	$33.71	126.73% Upside
INDV Indivior	3.25	Buy	$17.00	8.97% Upside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.00	29.87% Upside

Current Analyst Ratings Breakdown

Latest ATAI, INDV, RXRX, and DNLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
7/3/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$5.00
7/2/2025	ATAI atai Life Sciences	Aegis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/2/2025	ATAI atai Life Sciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $12.00
6/30/2025	INDV Indivior	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $22.00
6/16/2025	RXRX Recursion Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $5.00
5/20/2025	ATAI atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/13/2025	ATAI atai Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $29.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI atai Life Sciences	$310K	1,744.90	N/A	N/A	$0.69 per share	3.91
DNLI Denali Therapeutics	$330.53M	6.54	N/A	N/A	$8.53 per share	1.74
INDV Indivior	$1.19B	N/A	$1.85 per share	8.45	($2.52) per share	N/A
RXRX Recursion Pharmaceuticals	$59.82M	36.63	N/A	N/A	$2.61 per share	2.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI atai Life Sciences	-$149.27M	-$0.91	N/A	N/A	N/A	N/A	-102.10%	-77.55%	8/12/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.67	N/A	N/A	N/A	N/A	-35.90%	-32.41%	7/30/2025 (Estimated)
INDV Indivior	$2M	-$0.31	N/A	9.12	N/A	-4.02%	-97.29%	15.74%	7/24/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$463.66M	-$1.77	N/A	N/A	N/A	-961.32%	-74.70%	-54.02%	8/6/2025 (Estimated)

Latest ATAI, INDV, RXRX, and DNLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	RXRX Recursion Pharmaceuticals	-$0.34	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	ATAI atai Life Sciences	-$0.13	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	DNLI Denali Therapeutics	-$0.73	N/A	N/A	N/A	N/A	N/A
7/24/2025	Q2 2025	INDV Indivior	$0.25	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	ATAI atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A
5/5/2025	Q1 2025	RXRX Recursion Pharmaceuticals	-$0.44	-$0.50	-$0.06	-$0.50	$18.12 million	$14.75 million
4/24/2025	Q1 2025	INDV Indivior	$0.22	$0.41	+$0.19	$0.38	$240.13 million	$266.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI atai Life Sciences	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
INDV Indivior	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI atai Life Sciences	0.08	4.07	4.07
DNLI Denali Therapeutics	N/A	9.56	9.56
INDV Indivior	N/A	0.88	0.72
RXRX Recursion Pharmaceuticals	0.02	4.11	4.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI atai Life Sciences	28.41%
DNLI Denali Therapeutics	92.92%
INDV Indivior	60.33%
RXRX Recursion Pharmaceuticals	89.06%

Insider Ownership

Company	Insider Ownership
ATAI atai Life Sciences	26.80%
DNLI Denali Therapeutics	12.50%
INDV Indivior	N/A
RXRX Recursion Pharmaceuticals	8.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI atai Life Sciences	80	200.34 million	146.65 million	Optionable
DNLI Denali Therapeutics	430	145.28 million	127.12 million	Optionable
INDV Indivior	1,051	N/A	N/A	Not Optionable
RXRX Recursion Pharmaceuticals	400	406.50 million	372.23 million	Optionable

ATAI, INDV, RXRX, and DNLI Headlines

Recent News About These Companies

Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?

July 16 at 11:01 AM | zacks.com

D.A. Davidson & CO. Raises Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

July 11, 2025 | marketbeat.com

Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing

July 10, 2025 | zacks.com

Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating

July 10, 2025 | msn.com

Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia

July 9, 2025 | insidermonkey.com

Recursion Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RXRX)

July 9, 2025 | marketbeat.com

RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program

July 9, 2025 | zacks.com

Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M

July 9, 2025 | finance.yahoo.com

10 Under-the-Radar Tech Stocks With Incredible Growth Potential

July 9, 2025 | fool.com

Recursion Pharmaceuticals (RXRX) Drops on Profit-Taking

July 8, 2025 | insidermonkey.com

Recursion Pharmaceuticals: Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

July 8, 2025 | finanznachrichten.de

Recursion Pharmaceuticals Stock Gains on Plans to Buy Drug-Development Interest from Rallybio

July 8, 2025 | marketwatch.com

Recursion Pharmaceuticals stock soars after acquiring HPP treatment from Rallybio

July 8, 2025 | in.investing.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 6.7% Higher - Should You Buy?

July 8, 2025 | marketbeat.com

Recursion Pharmaceuticals' (RXRX) Buy Rating Reaffirmed at Needham & Company LLC

July 8, 2025 | marketbeat.com

10 Stocks Crash Hard Alongside Wall Street

July 8, 2025 | insidermonkey.com

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

July 8, 2025 | finance.yahoo.com

What's Happening With RXRX Stock?

July 8, 2025 | forbes.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 6.2% - Here's Why

July 7, 2025 | marketbeat.com

Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?

July 7, 2025 | zacks.com

Why Recursion Pharmaceuticals (RXRX) Outpaced the Stock Market Today

July 3, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI, INDV, RXRX, and DNLI Company Descriptions

atai Life Sciences NASDAQ:ATAI

$2.70 +0.05 (+1.89%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$2.70 +0.00 (+0.19%)

As of 08:53 AM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Denali Therapeutics NASDAQ:DNLI

$14.87 +0.70 (+4.94%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$14.88 +0.01 (+0.09%)

As of 08:43 AM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Indivior NASDAQ:INDV

$15.60 +0.22 (+1.43%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$15.45 -0.15 (-0.96%)

As of 08:54 AM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Recursion Pharmaceuticals NASDAQ:RXRX

$5.39 +0.17 (+3.26%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$5.50 +0.12 (+2.13%)

As of 08:55 AM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time